Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ:GLUE
Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$19.78
-$0.20(-2.99%)
At close: 4:00 PM EST
$19.78
-$0.20(-2.99%)
Day’s Range― - ―
52-Week Range$4.12 - $25.77
Previous CloseN/A
Volume283.19K
Average Volume (3M)772.73K
Market Cap
$1.47B
Enterprise Value$1.16B
Total Cash (Recent Filing)$666.22M
Total Debt (Recent Filing)$39.06M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding84,479,416
10 Day Avg. Volume898,938
30 Day Avg. Volume772,734
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue27.07
Enterprise Value/Gross Profit28.41
Enterprise Value/Ebitda-8.31
Forecast
1Y Price Target
$32.80Price Target Upside65.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$46.05M
Bulls Say, Bears Say
Bulls Say
Proprietary QuEEN PlatformThe QuEEN discovery engine targets previously undruggable proteins via induced degradation, creating a durable scientific moat. A platform-driven model supports multiple programs, spreads R&D leverage across assets, and enhances long-term partner and licensing optionality.
Low Leverage And Expanding AssetsLow debt and expanding assets give the company financial flexibility to fund clinical programs and absorb periodic cash burn. Manageable leverage reduces refinancing risk and supports strategic choices like partnering, licensing, or selective internal Phase 2 investments.
Partner Validation & Program AccelerationActive collaborations with large pharma and imminent partner-led Phase 2 starts materially de-risk programs, provide external funding and regulatory development resources, and signal external validation that can accelerate clinical development and milestone revenue potential.
Bears Say
Cash-flow VolatilityRecent return to cash burn undermines runway and increases reliance on partner funding or new financing. Variable cash generation makes planning multiple simultaneous Phase 2 starts riskier and raises the probability of equity dilution if partner milestones do not bridge funding needs.
Large Trailing Net LossA substantial TTM net loss reflects high development costs outpacing revenues and drives persistent negative returns on equity. Ongoing losses pressure balance-sheet resources over time and increase the need for financing, which can constrain strategic flexibility.
Revenue Concentration & VolatilityRevenue is irregular and milestone-dependent, making top-line visibility weak and susceptible to partner timing. The company's recent sharp TTM revenue decline highlights concentration and timing risk, complicating funding and operational planning for multi-program advancement.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics, Inc.’s price range in the past 12 months?
Monte Rosa Therapeutics, Inc. lowest stock price was $4.12 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics, Inc.’s market cap?
Monte Rosa Therapeutics, Inc.’s market cap is $1.47B.
When is Monte Rosa Therapeutics, Inc.’s upcoming earnings report date?
Monte Rosa Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 60 days.
How were Monte Rosa Therapeutics, Inc.’s earnings last quarter?
Monte Rosa Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is Monte Rosa Therapeutics, Inc. overvalued?
According to Wall Street analysts Monte Rosa Therapeutics, Inc.’s price is currently Undervalued.
Does Monte Rosa Therapeutics, Inc. pay dividends?
Monte Rosa Therapeutics, Inc. does not currently pay dividends.
What is Monte Rosa Therapeutics, Inc.’s EPS estimate?
Monte Rosa Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. has 84,479,416 shares outstanding.
What happened to Monte Rosa Therapeutics, Inc.’s price movement after its last earnings report?
Monte Rosa Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -2.845%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.80 (65.82% Upside)
$32.80 (65.82% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 666.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $427.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
254.32%
12-Months-Change
Fundamentals
Return on Equity
-40.99%
Trailing 12-Months
Asset Growth
87.29%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$32.80
▲(65.82% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.16% Insiders
14.93% Mutual Funds
57.33% Other Institutional Investors
2.01% Public Companies and
Individual Investors